Cmax and Tmax describe different properties of the same sildenafil concentration-time profile. The Cmax vs Tmax distinction separates maximum observed concentration from the timing coordinate at which that maximum occurs. The peak curve shows how concentration rises, reaches its maximum, and subsequently declines, while peak window basics place that maximum within a broader temporal region. The mechanistic rise toward the maximum can be described as an absorption peak, with absorption rate and absorption mechanism determining how systemic input develops. Upstream gastric emptying impact and intestinal uptake influence when absorbed sildenafil becomes available, while the first-pass effect can remove parent drug before systemic circulation. The resulting bioavailability link connects presystemic processes with systemic exposure. Thus, Cmax reflects concentration magnitude, whereas Tmax reflects timing, and both emerge from the integrated balance of input and disposition.
The Tmax definition identifies the time coordinate associated with maximum observed plasma concentration, but Tmax should not be equated with pharmacodynamic onset. The Tmax vs onset distinction separates a PK timing measurement from the beginning of a biological response. Cmax likewise describes a measured concentration maximum rather than a direct statement about effect magnitude. Dose-related variables can alter the concentration profile, with dose comparison, dose escalation impact, and the dose response curve providing conceptual frameworks for interpreting changing exposure relationships. Food-associated modifiers such as fatty food impact and light meal impact can alter the upstream input pattern, while alcohol impact on peak describes another potential modifier of peak-related PK behavior. These factors can change Cmax, Tmax, or both, depending on which processes within the concentration-time pathway are affected.
Metabolic capacity provides another layer connecting upstream input with the observed peak. Enzyme inhibitors impact and enzyme inducers impact can alter metabolic processes and thereby change the amount or timing of parent sildenafil appearing systemically. The resulting concentration profile may differ between individuals because of interindividual variation and genetic variability. These differences can affect Cmax, Tmax, curve shape, or the duration of the peak region without changing the definitions of either parameter. Mechanistically, the timeline can therefore be represented as absorption, systemic input, peak formation, Tmax, and subsequent decline, with presystemic extraction and distribution influencing the observed profile between these stages. Cmax answers the question of how high the measured concentration becomes, whereas Tmax answers when that maximum occurs. The absorption peak describes the rise toward that maximum rather than defining a separate clinical endpoint. This framework remains descriptive and does not provide dosing, treatment, or safety recommendations.
Cmax is the maximum observed concentration in a measured sildenafil plasma concentration-time profile. Tmax is the corresponding PK timing coordinate of that maximum. The Cmax vs Tmax distinction is therefore fundamental: Cmax describes magnitude, whereas Tmax describes time. The peak curve provides the graphical context in which both parameters are observed, and peak window basics describe the broader region surrounding the concentration maximum. The rise toward Cmax depends on systemic input, with absorption rate describing temporal input and absorption mechanism describing the processes that establish that input. Upstream gastric emptying impact can influence intestinal delivery, while intestinal uptake establishes entry into the portal pathway. These mechanisms jointly shape the concentration-time profile before Cmax and Tmax are observed.
Tmax should be interpreted as a PK coordinate rather than as a direct marker of pharmacodynamic onset. The Tmax definition identifies the time at which the observed concentration reaches its maximum, while Tmax vs onset emphasizes that maximum concentration and biological response onset are separate concepts. Cmax similarly represents a measured concentration maximum and does not by itself specify the magnitude of a downstream biological response. The peak effect physiology concept provides a bridge between peak exposure and pharmacodynamic interpretation without making the PK parameter itself a clinical endpoint. The distribution phase is also relevant because concentrations can change after systemic appearance as drug moves between compartments. Consequently, the maximum observed plasma concentration reflects the integrated balance of absorption, presystemic loss, distribution, and elimination rather than absorption alone.
The concentration maximum emerges when the net rate of systemic drug input and the net rate of drug removal intersect within the observed profile. The first-pass effect can reduce the amount of parent sildenafil reaching systemic circulation, while the bioavailability link connects this presystemic loss with systemic availability. The absorption rate can influence how rapidly concentration rises, but the eventual Cmax and Tmax also depend on distribution and elimination. The peak curve therefore represents an integrated PK outcome. A change in absorption may alter both peak magnitude and timing, whereas a change in systemic disposition may alter the decline and shift the maximum. Interpreting Cmax and Tmax separately helps identify whether an observed difference primarily concerns concentration magnitude, temporal position, or both. This separation is essential for neutral mechanistic interpretation of sildenafil PK.
Peak concentration refers to the concentration maximum within the observed sildenafil PK curve. The peak curve shows the progression from systemic input through rising concentration, maximum concentration, and decline. The absorption peak is not a separate concentration parameter; it describes the mechanistic rise toward Tmax that is driven substantially by absorption processes. The absorption rate influences how rapidly systemic input develops, while the absorption mechanism describes the processes generating that input. Gastric emptying impact can alter when sildenafil reaches intestinal absorption sites, and intestinal uptake determines transfer from the gastrointestinal environment into the portal pathway. The first-pass effect can reduce parent drug before systemic circulation. Together these mechanisms determine the amount and timing of sildenafil available to form the observed peak.
The Tmax mechanism is the combined set of PK processes that determine when maximum concentration is reached. The Tmax definition identifies the resulting time coordinate, while Cmax vs Tmax separates that timing from the magnitude of the maximum. A delayed absorption profile can move Tmax later, while a faster input profile can move the maximum earlier when other processes remain comparable. However, Tmax is not determined by absorption alone. The distribution phase, systemic clearance, and the changing balance between input and removal all contribute to the final position of the maximum. The Tmax vs onset distinction is therefore important because Tmax is a concentration-time coordinate rather than a direct measure of pharmacodynamic onset. The peak window basics framework places the maximum within a broader temporal context.
Peak concentration and Tmax can change independently or together. A process that increases systemic input may increase Cmax while producing little change in Tmax if the temporal shape remains similar. Conversely, a delayed input profile may shift Tmax without producing a proportionate change in peak magnitude. The bioavailability link describes the relationship between systemic availability and upstream processes, while dose PK relationship provides a framework for relating input magnitude to exposure. Dose absorption limit addresses conceptual constraints on input, and dose response curve connects exposure concepts to downstream response models. These relationships should not be collapsed into a single parameter. Cmax remains a concentration measure, Tmax remains a timing measure, and the absorption peak remains a mechanistic description of the rise toward the maximum. Their combined interpretation describes the shape and timing of sildenafil systemic exposure.
| Component | Mechanistic Basis | Interpretation |
|---|---|---|
| Absorption rate | Determines the temporal pattern of sildenafil entering systemic input pathways. | Contributes to the rising portion of the concentration-time curve. |
| First-pass extraction | Removes a portion of parent sildenafil before systemic circulation. | Can alter the amount available for peak formation. |
| Cmax | Represents the maximum observed plasma concentration. | Describes peak concentration magnitude. |
| Tmax | Marks the time coordinate of maximum observed concentration. | Describes peak timing rather than concentration magnitude. |
| Distribution | Redistributes drug after systemic appearance across relevant compartments. | Can influence the concentration-time shape around and after the maximum. |
| Peak window | Represents the temporal region surrounding the concentration maximum. | Provides context for interpreting peak timing and curve shape. |
Cmax and Tmax emerge from several linked PK layers rather than from a single absorption event. The absorption mechanism establishes how sildenafil enters the body, while the absorption rate determines the temporal character of that input. Gastric emptying impact can influence when intestinal delivery occurs, and intestinal uptake establishes the portal input available for subsequent metabolism. The first-pass effect can reduce parent drug before systemic circulation, with the bioavailability link describing the resulting relationship between absorbed input and systemic availability. After systemic appearance, the distribution phase changes concentration as drug moves among compartments. The resulting profile determines both Cmax and Tmax. Thus, neither parameter should be attributed exclusively to gastrointestinal absorption because the observed maximum reflects the combined behavior of input and disposition.
The Cmax vs Tmax framework separates concentration magnitude from timing. Cmax depends on the amount and rate of systemic input as well as the processes removing drug from the measured compartment. Tmax depends on the temporal balance between those processes. The peak curve captures this balance graphically, while peak window basics provide a broader interpretation of the period surrounding the maximum. The Tmax definition identifies the time coordinate, and Tmax vs onset prevents that coordinate from being interpreted as a direct biological onset measure. Peak effect physiology can then be considered as a separate PK/PD layer. This separation allows mechanistic descriptions to remain precise even when several processes influence the same observed concentration-time profile.
Dose and metabolic modifiers can change the observed relationship between Cmax and Tmax. Dose comparison describes differences in input magnitude, while dose escalation impact considers how changing input can alter exposure patterns. Dose PD relationship connects exposure to downstream response models, but it does not redefine either PK parameter. Metabolic modifiers such as enzyme inhibitors impact and enzyme inducers impact can alter the amount of parent sildenafil surviving metabolic processes. Food-related factors such as fatty food impact may alter the timing or extent of systemic input, while alcohol impact on peak represents another potential modifier. The resulting changes may affect Cmax, Tmax, or both, depending on the affected PK layer and its relationship to the rest of the concentration-time system.
Food-associated changes can influence the timing and shape of sildenafil systemic input and consequently affect Cmax or Tmax. Timing before meal and timing after meal describe temporal relationships between food exposure and drug input rather than prescribing an administration strategy. Fatty food impact and light meal impact describe different food-related PK conditions that may influence gastrointestinal transit, absorption, or systemic appearance. Changes in gastric delivery can be represented through gastric emptying impact, which acts upstream of intestinal absorption. The resulting change in input can modify the rising portion of the concentration-time curve and potentially alter the timing or magnitude of the maximum. Cmax and Tmax therefore provide two separate readouts of a potentially modified profile: one measures the maximum concentration, while the other identifies when that maximum occurs.
Alcohol represents another modifier that can influence observed peak behavior through multiple PK pathways. The alcohol impact on peak concept concerns changes in concentration-time behavior, while drug interactions peak provides a broader framework for interaction-related changes in peak formation. Metabolic mechanisms can involve enzyme inhibitors impact or enzyme inducers impact, potentially changing the amount of parent sildenafil surviving metabolic processes. These changes can alter Cmax by changing systemic availability or clearance, while Tmax may shift if the temporal balance between input and disposition changes. The Cmax vs Tmax distinction remains essential because a higher or lower maximum does not automatically imply a later or earlier maximum. The concentration-time curve must be considered as an integrated outcome of all active PK processes.
Timing-related modifiers can interact with dose and systemic disposition to produce complex concentration-time changes. Dose PK relationship describes the relationship between input and exposure, while dose escalation impact addresses how changing input magnitude can affect the resulting profile. Timing optimization and dose optimization are included only as conceptual topics concerning PK modeling and are not recommendations. Interaction summary provides a framework for organizing interaction mechanisms, while peak curve shows how those mechanisms appear in the observed concentration-time pattern. The resulting Cmax and Tmax should therefore be interpreted according to whether a modifier primarily changes systemic availability, input rate, metabolic capacity, distribution, or elimination. No single modifier necessarily determines both peak magnitude and peak timing. Instead, each observed profile reflects the combined effects of multiple PK layers operating across the same timeline.
| Modifier | PK/PD Link | Cmax/Tmax Impact |
|---|---|---|
| Meal timing | Can alter gastrointestinal delivery and the timing of systemic input. | May change the magnitude or timing of the observed peak. |
| Fatty food | Can modify gastrointestinal and absorption-related PK behavior. | May reshape the rising curve and influence Cmax or Tmax. |
| Light meal | Represents a distinct food-associated input condition. | Can modify the temporal context of peak formation. |
| Alcohol | May influence gastrointestinal, metabolic, or systemic PK processes. | Can alter peak concentration, timing, or curve shape. |
| Enzyme inhibition | Reduced metabolic activity can increase parent-drug persistence. | May change Cmax and potentially shift Tmax depending on the affected pathway. |
| Enzyme induction | Increased metabolic capacity can increase drug loss through relevant pathways. | May reduce Cmax and can alter Tmax when systemic input-disposition balance changes. |
Cmax and Tmax can vary between individuals because the processes shaping systemic input and disposition are not identical across subjects. Interindividual variation provides the broad framework for differences in PK parameters, while genetic variability can contribute to differences in metabolic capacity. Age impact may affect physiological processes relevant to absorption or disposition, while hepatic function impact can influence metabolic handling. Renal function impact concerns later elimination processes rather than directly defining absorption. Metabolic rate impact provides another conceptual determinant of concentration-time behavior. Because these factors act at different stages, variability in Cmax does not necessarily predict an equivalent variability in Tmax. One individual may show a different maximum concentration because of altered exposure magnitude, while another may show a different peak time because of altered input or disposition timing.
Variability in absorption can alter the rising phase of the sildenafil concentration-time curve and therefore influence the position of Tmax. Gastric emptying impact can change when drug reaches intestinal sites, while intestinal uptake determines the transfer into the portal pathway. The first-pass effect can then alter the amount of parent drug reaching systemic circulation. The bioavailability link captures the relationship between these upstream processes and systemic availability. Once systemic, drug undergoes distribution and elimination, with the distribution phase contributing to the observed concentration-time shape. The Cmax vs Tmax framework allows the resulting variability to be described separately as magnitude or timing. This is important because biological variation can influence one coordinate more strongly than the other, and the two measures should not be treated as interchangeable summaries of exposure.
Population-level analysis can distinguish typical PK behavior from variability around that behavior. Peak window modeling can represent differences in peak timing and curve shape, while population pharmacokinetics provides a framework for estimating typical parameters and between-subject variability. Clinical peak data can supply observed concentration-time measurements, and peak window summary can organize the temporal features of the resulting profiles. Such analyses can show whether variability primarily affects Cmax, Tmax, or both. The interpretation remains descriptive because a statistical difference in a PK parameter does not by itself establish a biological or clinical consequence. Cmax remains the maximum observed concentration, Tmax remains its timing coordinate, and the absorption peak remains the mechanistic rise toward that maximum. This terminology preserves a clear distinction between measured PK properties and the biological processes that produce them.
The integrated sildenafil PK timeline begins with absorption and proceeds toward systemic appearance, peak formation, Tmax, and the subsequent decline. The absorption mechanism establishes how drug crosses gastrointestinal barriers, while absorption rate determines the temporal pattern of input. Gastric emptying impact influences when drug reaches intestinal sites, and intestinal uptake establishes portal input. The first-pass effect can reduce parent sildenafil before systemic circulation, with the bioavailability link connecting presystemic loss to systemic availability. After systemic appearance, the concentration rises toward its observed maximum. Tmax definition identifies the timing coordinate of that maximum, while Cmax describes the maximum concentration itself. The peak curve represents this complete concentration-time sequence and allows the separate roles of magnitude and timing to be visualized.
Distribution and downstream PK processes continue to shape the profile after systemic appearance. The distribution phase describes movement among compartments and can influence the concentration measured in plasma. The Cmax vs Tmax distinction remains useful because Cmax reflects the maximum observed concentration while Tmax identifies when that maximum occurs. The peak window basics framework places the maximum within a broader temporal region, while Tmax vs onset preserves the difference between a PK coordinate and biological onset. The peak effect physiology concept can then connect peak exposure with downstream pharmacodynamic interpretation. Dose PD relationship and dose response curve provide broader exposure-response frameworks without changing the definitions of Cmax or Tmax. The result is a layered PK/PD timeline in which each coordinate retains its specific mechanistic meaning.
Modeling provides a way to integrate these linked processes and represent differences among observed profiles. Peak window modeling can describe changes in peak magnitude, timing, and curve shape, while population pharmacokinetics can separate typical parameter values from between-subject variability. Clinical peak data provide measured concentration-time observations, and peak window summary organizes their peak-related characteristics. Food and interaction effects can be incorporated through concepts such as fatty food impact, drug interactions peak, and enzyme inhibitors impact. These modifiers may affect systemic availability, input timing, or disposition and can therefore influence Cmax, Tmax, or both. The integrated interpretation remains neutral: absorption establishes input, first-pass processes modify parent-drug availability, distribution shapes systemic concentration, and the balance of input and removal determines the observed maximum and its timing.
| Timeline Component | Mechanistic Influence | Role in Cmax/Tmax |
|---|---|---|
| Absorption | Introduces sildenafil into the systemic input pathway over time. | Shapes the rising concentration profile and contributes to peak formation. |
| First-pass effect | Removes a portion of parent sildenafil before systemic circulation. | Can change the amount available for the observed peak. |
| Systemic appearance | Introduces surviving parent drug into the measured circulation. | Establishes the effective input profile that drives concentration rise. |
| Distribution | Moves drug between relevant compartments after systemic entry. | Contributes to the concentration-time shape around and after the maximum. |
| Tmax | Identifies the time coordinate at maximum observed concentration. | Describes peak timing independently from peak magnitude. |
| Cmax | Represents the maximum observed concentration in the profile. | Describes the magnitude of the concentration peak. |
Cmax is the maximum observed concentration of sildenafil within a measured plasma concentration-time profile. It is a pharmacokinetic parameter describing concentration magnitude, not a direct measure of biological effect or a treatment target. Cmax emerges from the combined influence of systemic input and drug disposition. Absorption rate affects the rising portion of the curve, while presystemic metabolism, distribution, and elimination also contribute to the final observed maximum. Because Cmax is a concentration measure, it should be distinguished from Tmax, which describes the timing of the maximum. Two concentration-time profiles can therefore have similar Tmax values but different Cmax values, or similar Cmax values but different Tmax values. Cmax is interpreted from observed or modeled PK data.
Tmax is the pharmacokinetic timing coordinate associated with the maximum observed plasma concentration of sildenafil. It identifies when the concentration-time curve reaches its highest measured point. Tmax is therefore a time-related PK parameter rather than a concentration measure. It should also be distinguished from biological onset because the time of maximum concentration does not necessarily represent the beginning of a pharmacodynamic response. Tmax emerges from the balance between systemic input and processes removing or redistributing drug. Changes in absorption timing, presystemic extraction, distribution, or elimination can influence its position. Tmax is best interpreted together with the concentration-time curve and Cmax, because timing and magnitude represent different properties of the same PK profile.
Peak concentration means the maximum concentration observed within a sildenafil concentration-time curve. It corresponds to Cmax when the parameter is defined from the measured plasma profile. The peak is not simply a property of absorption because systemic disposition also contributes to the point at which concentration stops rising and begins declining. The amount and rate of systemic input, presystemic metabolism, distribution, and elimination collectively shape the curve. Peak concentration therefore describes the magnitude of the observed maximum, while Tmax describes when that maximum occurs. The surrounding peak window provides additional temporal context for interpreting the curve. Peak concentration is a descriptive PK property and does not by itself establish a pharmacodynamic outcome, therapeutic target, or clinical recommendation.
An absorption peak is a mechanistic description of the rise in systemic concentration toward Tmax that is driven substantially by absorption processes. It is not a separate standard PK parameter equivalent to Cmax or Tmax. The absorption rate determines how quickly drug enters the systemic input pathway, while gastrointestinal delivery and intestinal uptake establish when that input occurs. Presystemic metabolism can reduce the amount of parent drug reaching systemic circulation, and distribution and elimination continue to influence the observed concentration curve. Consequently, the rise toward the concentration maximum reflects several connected processes rather than absorption alone. The term absorption peak is useful for describing the input-related portion of peak formation while keeping it distinct from Cmax, which measures the maximum concentration, and Tmax, which measures its timing.
The first-pass effect refers to presystemic metabolism of absorbed parent sildenafil before systemic circulation. By removing some parent drug before systemic appearance, it can change the amount available to form the concentration-time peak and therefore influence Cmax. Its effect on Tmax depends on how presystemic extraction interacts with the timing and magnitude of systemic input and with later disposition. A change in first-pass extraction does not automatically produce a proportional change in peak timing because Tmax reflects the overall balance of input and removal. The relationship is therefore mechanistic rather than one-to-one. Cmax describes the magnitude of the observed maximum, Tmax describes when that maximum occurs, and first-pass metabolism is one upstream process that can contribute to both properties.
Food can affect sildenafil Cmax and Tmax when it changes gastrointestinal conditions that influence drug delivery, absorption, or other PK processes. A meal can alter the timing of gastric emptying and therefore the arrival of drug at intestinal absorption sites. Changes in the rate or extent of systemic input can then modify the rising portion of the concentration-time curve. Depending on the mechanism and magnitude of the food effect, the observed maximum may differ in concentration, timing, or both. Food effects should not automatically be interpreted as direct changes in first-pass metabolism because several PK layers can contribute to the observed profile. Cmax remains the maximum concentration, while Tmax remains the timing coordinate of that maximum. These parameters should therefore be interpreted from the complete concentration-time curve.
Alcohol can be considered a potential modifier of sildenafil concentration-time behavior through effects on gastrointestinal, metabolic, or systemic PK processes. The specific mechanism determines whether the observable change primarily affects input timing, peak concentration, peak timing, or overall exposure. A change in gastrointestinal conditions could modify the rising portion of the curve, while metabolic effects could alter the amount of parent sildenafil remaining in circulation. Because Cmax and Tmax describe different properties, an observed change in one does not necessarily imply a proportional change in the other. The concentration-time curve should therefore be evaluated as an integrated profile. Alcohol-related peak behavior is a mechanistic PK topic and does not by itself establish a clinical outcome or provide instructions concerning administration.
Enzyme inhibition means that the activity of a metabolic pathway is reduced. If the affected pathway contributes to sildenafil metabolism, inhibition can change the amount of parent drug remaining available in the systemic circulation. This may increase or otherwise alter Cmax depending on the pathway and its contribution to overall clearance or presystemic extraction. Tmax may also change if the altered metabolic process changes the temporal balance between systemic input and drug removal. However, a change in metabolic activity does not guarantee a specific direction or magnitude of Tmax change because absorption, distribution, and other elimination pathways also contribute. Enzyme inhibition is therefore interpreted as one mechanistic modifier within the complete PK system rather than as a direct synonym for a particular Cmax or Tmax outcome.
Enzyme induction refers to increased expression or functional capacity of a metabolic pathway. If the induced pathway contributes to sildenafil metabolism, greater metabolic activity can alter the amount of parent drug surviving presystemic or systemic metabolism. The resulting concentration-time profile may therefore show a change in Cmax and, depending on the timing of input and disposition, a change in Tmax. The exact effect depends on the contribution of the induced pathway relative to absorption, distribution, and other elimination processes. Enzyme induction should consequently be viewed as a mechanism that changes metabolic capacity rather than as a parameter that directly determines peak concentration or timing. Cmax and Tmax remain observed PK outcomes produced by the integrated concentration-time system.
Dose changes the amount of sildenafil entering the PK system, so it can influence concentration magnitude and potentially the timing of the observed maximum. The relationship is not necessarily proportional because absorption, presystemic extraction, metabolic capacity, distribution, and elimination can all affect exposure. Cmax generally describes how high the measured concentration becomes, while Tmax describes when the maximum occurs. Changing input magnitude can therefore alter Cmax without producing an equivalent change in Tmax, although nonlinear or capacity-related processes may affect both. Dose should be treated as an input variable within a PK model rather than as a definition of either peak parameter. The interpretation of dose-related changes remains mechanistic and descriptive and does not imply a recommended administration strategy.
Cmax and Tmax can vary between individuals because the physiological processes governing absorption and disposition differ across subjects. Gastrointestinal transit, intestinal uptake, metabolic activity, distribution, and elimination can each contribute to variation in the concentration-time profile. Genetic differences can influence metabolic pathways, while age and other physiological characteristics can affect relevant PK processes. Because these mechanisms act at different stages, variability in Cmax does not necessarily predict equivalent variability in Tmax. One person may show a different maximum concentration because of altered systemic availability, while another may show a different peak time because of altered absorption or disposition timing. Population PK methods can represent these differences by estimating typical PK parameters and variability around them rather than assuming identical concentration-time behavior for every individual.
Cmax and Tmax are commonly derived from modeled or observed concentration-time profiles. A PK model first describes processes such as absorption, systemic input, distribution, metabolism, and elimination. The resulting concentration-time curve then contains a maximum concentration and an associated time coordinate. Cmax is the value of that maximum, while Tmax is the time at which it occurs. Modeling can also represent uncertainty, between-subject variability, and changes in input or disposition parameters. Peak-window models can characterize broader temporal features around the maximum. Importantly, Cmax and Tmax are outcomes of the modeled system rather than independent mechanisms. Their values depend on the assumptions and parameters used to represent the underlying PK processes and on the quality and timing of the available concentration measurements.
Population pharmacokinetics describes concentration-time behavior across individuals by estimating typical parameter values and variability around those values. Cmax and Tmax can be treated as derived features of individual or simulated profiles, allowing the model to characterize differences in peak magnitude and timing. Variability may arise from differences in absorption, presystemic metabolism, distribution, or elimination. Covariates can sometimes explain a portion of observed variability when supported by data and an appropriate model structure. Population PK therefore does not require every subject to share one identical Cmax or Tmax. Instead, it describes a distribution of plausible PK behavior around a population-level estimate. This framework helps distinguish systematic patterns from residual variability while preserving the separate meanings of Cmax as concentration magnitude and Tmax as peak timing.